Cargando…

Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study

Objectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50 mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50 mg/day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizusawa, Takaki, Hara, Noboru, Obara, Kenji, Isahaya, Etsuko, Nakagawa, Yuki, Takahashi, Kota
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095445/ https://www.ncbi.nlm.nih.gov/pubmed/21603217 http://dx.doi.org/10.1155/2011/804583

Ejemplares similares

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Efficacy of Naftopidil as a Medical Expulsive Therapy in Japanese Men With Ureteral Stones: A Prospective Randomized Controlled Study
por: Ohgaki, Kenji
Publicado: (2019)

Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia
por: Morita, Tatsuo, et al.
Publicado: (2013)

In Vitro Effects of Plasma Collected From Rats Administered Naftopidil on Whole Urinary Bladder Preparation Isolated From Rats
por: Hattori, Tsuyoshi, et al.
Publicado: (2019)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
por: Tanuma, Yasushi, et al.
Publicado: (2017)

Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice
por: Urushiyama, Hirokazu, et al.
Publicado: (2019)

Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips
por: Hattori, Tsuyoshi, et al.
Publicado: (2017)

Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design
por: Sung, Hyun Hwan, et al.
Publicado: (2020)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement
por: Perumal, Chenthil, et al.
Publicado: (2015)

Lower urinary tract symptoms in men
por: Hollingsworth, John M, et al.
Publicado: (2014)

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

Human UDP-Glucuronosyltransferase 2B4 and 2B7 Are Responsible for Naftopidil Glucuronidation in Vitro
por: Liu, Xia-Wen, et al.
Publicado: (2018)

Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil
por: Tanuma, Yasushi, et al.
Publicado: (2021)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

Systematic synthesis of a 6-component organic-salt alloy of naftopidil, and pentanary, quaternary and ternary multicomponent crystals
por: Dandela, Rambabu, et al.
Publicado: (2018)

Effects of High Concentrations of Naftopidil on Dorsal Root-Evoked Excitatory Synaptic Transmissions in Substantia Gelatinosa Neurons In Vitro
por: Uta, Daisuke, et al.
Publicado: (2018)

Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α(1D)-adrenoceptor antagonists
por: Xu, Wei, et al.
Publicado: (2017)

Drug Repositioning of the α(1)-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?
por: Florent, Romane, et al.
Publicado: (2020)

Lower urinary-tract symptoms and testosterone in elderly men
por: Yassin, Aksam A., et al.
Publicado: (2008)

Patient with inguinal hernia containing the urinary bladder complicated by bladder stones
por: Inage, Kota, et al.
Publicado: (2019)

Limited impact of a nudge comment in promoting de-escalation to first-generation cephalosporins in urinary tract infections
por: Brenneman, Martin T., et al.
Publicado: (2022)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Effects of naftopidil on double-J stent-related discomfort: a multicenter, randomized, double-blinded, placebo-controlled study
por: Oh, Jong Jin, et al.
Publicado: (2017)

Medical expulsive therapy for ureter stone using naftopidil: A multicenter, randomized, double-blind, and placebo-controlled trial
por: Cho, Sung Yong, et al.
Publicado: (2017)

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
por: Chung, Mun Su, et al.
Publicado: (2017)

Inhibition of Liquid–Liquid Phase Separation for Breaking the Solubility Barrier of Amorphous Solid Dispersions to Improve Oral Absorption of Naftopidil
por: Fukiage, Masafumi, et al.
Publicado: (2022)

Does Urinary Bladder Shape Affect Urinary Flow Rate in Men with Lower Urinary Tract Symptoms?
por: Ateşçi, Yusuf Ziya, et al.
Publicado: (2014)

The effect of colpectomy on lower urinary tract function in transgender men
por: de Rooij, Freek P. W., et al.
Publicado: (2022)

Urinary Tract Infections in Men in Primary Care in Catalonia, Spain
por: Fernández-García, Silvia, et al.
Publicado: (2023)

Randomized Controlled Trial to Compare the Safety and Efficacy of Naftopidil and Tamsulosin as Medical Expulsive Therapy in Combination With Prednisolone for Distal Ureteral Stones
por: Kumar, Santosh, et al.
Publicado: (2013)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Erratum to “Does Urinary Bladder Shape Affect Urinary Flow Rate in Men with Lower Urinary Tract Symptoms?”
por: Ateşçi, Yusuf Ziya, et al.
Publicado: (2014)

Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2018)

Lower urinary tract symptoms and their severity in men subjected to prostate biopsy
por: Dobruch, Jakub, et al.
Publicado: (2014)

Men With Severe Lower Urinary Tract Symptoms Are at Increased Risk of Depression
por: Jeong, Won Sik, et al.
Publicado: (2015)

Erectile Dysfunction in Men with and without Lower Urinary Tract Symptoms in Nigeria
por: Adegun, Patrick Temi, et al.
Publicado: (2017)

Non-invasive evaluation of lower urinary tract symptoms (LUTS) in men
por: Mangat, Reshma, et al.
Publicado: (2018)

Lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis
por: Tomé, André Luiz Farinhas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b5gjv6apuujqtivlesbk2tr4na